They might not always be easily identifiable, but millions of people across the globe are living with the debilitating symptoms of depression. This common mental disorder is thought to affect around 5% of the world’s adult population, with the pandemic … Read More
adherence data
In pursuit of better answers: WHO aims for higher quality clinical trial evidence with best-practice guidance
WHO cares. It’s now time you did Why Change is Needed in Clinical Trials? The old adage tells us not to fix things that aren’t broken. Logic suggests, therefore, that whenever a fix is being applied, things aren’t working as … Read More
WHO Cares: A pro-adherence strategy means little without the drive for better data quality
Enhancing Adherence in Clinical Trials: A Strategic Imperative When a high-profile authority in the medical world, such as the World Health Organization (WHO), publishes guidelines on best practices in clinical trials, the industry takes note. Aiming for Reform and Improvement … Read More
From Sealed Envelopes to Smart Adherence: Why Clinical Trials Must Embrace Digital Innovation
Nostalgia can trick us into thinking that things were better in the “good old days”. But the world of science is rarely a place where sentimentality should cloud better judgement. Rather, it is a place where questions, analysis and evidence … Read More
Protecting your investment: How clinical trial failings are costing the investor community
When bringing a new drug product to market, powerful motivating forces are involved. And while the potential for enhancing, or even extending, the lives of patients unquestionably takes primacy, there is another inescapably influential factor in the mix: profitability. For … Read More
Drug dose reduction’s role in tackling Pharma 2.0’s profitability problem
The economic model that has underpinned the development of drug products for decades is currently under siege. Faced on one side with mounting pressure from payers to address affordability issues, pharmaceutical companies are facing ever more stringent regulatory requirements alongside … Read More
One size fails all? The weight of evidence for personalized dosing in oral GLP-1 therapies
In recent years, the pharmaceutical industry has borne witness to the meteoric rise of glucagon-like peptide-1 receptor agonist (GLP-1) therapies. Having fast become established as a potentially life-changing treatment for Type 2 diabetes and obesity, emerging evidence of the cardio and … Read More
AARDEX Group and Compliance Meds Technologies sign collaboration agreement
AARDEX Group, the global leader in medication adherence solutions, has today announced a collaboration agreement with Compliance Meds Technologies (CMT), a mobile-health technology solutions provider. AARDEX MEMS® Adherence Software with Compliance Meds Technologies CleverCap® In this cooperation, the partners will … Read More
Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management
Medication adherence is a vital component in managing chronic diseases effectively. However, it remains a significant challenge, with non-adherence rates reaching up to 50% among patients. This lack of adherence results in poor health outcomes and increased burdens on healthcare … Read More
Clinical trial failures: Are we counting the cost of poor adherence?
Clearly it is in no one’s interests for a clinical trial to fail. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. Beyond the sponsor’s missed commercial opportunity, there are missed opportunities to advance … Read More